Summary An immunoperoxidase technique has been used to detect the in vivo binding of a 2-nitroimidazole hypoxia marker in histochemical sections of a variety of excised canine tumours. The binding occurred 10-12 cell diameters away from tumour blood vessels, consistent with the expected location of hypoxic cells in tissues in which oxygen concentration gradients are established by diffusion. Hypoxic fractions ranging from 4 to 13% have been estimated on the basis of morphometric analysis of multiple tumour sections. The binding of the marker was restricted to the cytoplasm of the cells. The marker appeared in regions adjacent to necrosis but also in regions free of necrosis. As in earlier autoradiography studies, binding was occasionally observed in cells adjacent to tumour blood vessels. Generally, binding to normal tissues was not observed. However, binding to smooth muscle cells surrounding arterioles in some sections of normal tissue and tumour tissue was observed.
Viable, radioresistant hypoxic cells may compromise the effectiveness of radiation treatment of tumours (Bush et al., 1978; Thomlinson & Gray, 1955 ) but may also be targets for selective cytotoxins (Kennedy, 1987) . In either case, the detection and measurement of tumour hypoxia would be of prognostic value. A variety of methods have been used to detect and measure the oxygenation status in cells and tissues (for review see . Methods which have been investigated in clinical studies include oxygen electrodes (Gatenby et al., 1988) , intercapillary distance measurements (Awwad et al., 1986) and bioreductive binding of marker molecules (Urtasun et al., 1986) .
The development of tumour hypoxia is usually attributed to either diffusion limited (Franko & Sutherland, 1979; Kallman, 1972) or perfusion limited (Brown, 1979) oxygen supply. An important aspect of diffusion limited oxygen distribution is that hypoxia develops over a few cell diameters at the limit of the oxygen diffusion distance. A corollary is that the method chosen for detecting diffusion limited or 'chronic' hypoxia in tumours should respond to oxygen gradients on a cellular scale. One such method is the hypoxia marker approach (Chapman, 1979; Chapman et al., 1981; .
Nitroheterocyclic compounds such as substituted 2-nitroimidazoles bind selectively to hypoxic cells in tissue culture (Varghese & Whitmore, 1980) and it has been proposed that this binding could be used to measure tumour hypoxia in vivo (Chapman, 1979) . The binding is a metabolic process involving endogenous nitroreductases which convert the nitroheterocyclic compounds to binding intermediates in an oxygen dependent manner (Franko & Koch, 1984; Franko et al., 1987) . The binding occurs over the same oxygen concentration range as that observed for the radiobiological oxygen effect (Franko et al., 1987) ; it is localised to the hypoxic cells in which the intermediates are produced (Franko et al., 1984) ; and the intermediates incorporate the whole marker molecule (Raleigh et al., 1985) . The attractiveness of the hypoxia marker approach has led to a variety of studies which differ only in the label and detection technique used. Autoradiographic detection of 3H or 14C labels (Chapman et al., 1981; , positron emission tomographic visualisation of F-18 labels (Rasey et al., 1989) , gamma-ray scintigraphic detection of gamma emitting halogen labels (Jette et al., 1983) and magnetic resonance spectroscopy of F-19 labels Maxwell et al., 1989) (Raleigh et al., 1987) . Antibodies which recognise the marker molecule CCI-103F were used to locate hypoxic cells in histochemical sections of tumour tissues. The immunohistochemical approach can be quantified (Miller et al., 1989) and has considerable potential as a means of measuring tissue hypoxia. We have now extended our earlier studies to hypoxia marker detection in spontaneous canine tumours.
UN>0°2 OH OCH(CF3)2 Materials and methods
Marker synthesis and antibody production The hypoxia marker, 1-(2-hydroxy-3-(1,1,1,3,3,3-hexafluoroisopropoxypropyl)-2-nitroimidazole (CCI-103F) and rabbit polyclonal antibodies to protein-bound CCI-103F were prepared and characterised as previously published (Raleigh et al., , 1987 .
Spheroid culture and labelling Spheroids of EMT6/Ed tumour cells were prepared and exposed to 0.10 mM CCI-103F in an air-saturated medium for 3 h as described previously (Raleigh et al., 1987) . The labelling procedure produced no detectable cytotoxicity to cells in the spheroids. The spheroids were harvested, washed several times with saline to remove unbound drug and fixed by immersion in 95% ethanol at 4°C followed by routine paraffin embedding. Histochemical sections (4 1m) of the fixed spheroids tissue were prepared and processed through graded concentrations of ethanol into phosphate-buffered saline (PBS, pH 7.2) and labelled with a standard peroxidaseantiperoxidase technique (Wordinger et al., 1987 Paraffin blocks from each neoplasm were sectioned at 4 tim and stained by either avidin-biotin complex or peroxidase-antiperoxidase (PAP) methods. In the avidin-biotin method, sections were hydrated and exposed to rabbit anti-CCI-103F in PBS overnight at 4°C. Biotinylated goat antirabbit antibody was then applied to the sections for 1 h at 37C followed by incubation with streptavidin for 20 min. In the peroxidase-antiperoxidase method sections were prepared and exposed to 0.3% hydrogen peroxide, followed by goat non-immune serum and overnight incubation with rabbit anti-CCI-103F at 4°C. Peroxidase-conjugated goat antirabbit IgG was then applied to the sections followed by goat antiperoxidase IgG. The chromogen used to detect the presence of peroxidase was 1 % aminoethyl carbazole in phosphate buffered saline.
Based on the premise that cellular immunoreactivity reflects the presence of hypoxic cells, hypoxic fractions in the tumour tissues were measured by morphometric analysis as follows. Ten histological sections were selected randomly from each tumour. With a light microscope at 400 x magnification, a 5 x 5 ocular grid was used to select cells for counting after a modification of the method of Garcia et al. (1986) . In each section, five or more fields were counted in the haematoxylin and eosin stained sections to attain a total count of at least 500 cells. The numbers of labelled cells were then counted in the same fields using immunoreactivity to the PAP stain as the marker of hypoxic cells. An estimate of the error in determining hypoxic fraction using this approach was made by repeating the procedure three times with one heavily labelled tumour and one lightly labelled tumour and using the data to calculate the mean and standard deviation of the three independent measurements.
Results

Spheroids
The distribution of peroxidase labelling in spheroids exposed to CCI-103F in aerated culture medium ( Figure 1 ) was similar to that shown previously in autoradiographic and fluorescence immunohistochemical studies with confirming that the peroxidase labelling approach did not alter the labelling pattern of hypoxic cells in the spheroid model (Miller et al., 1989; Raleigh et al., 1987) . In particular, there is no labelling of either the outer, well-oxygenated or the central, necrotic regions of the spheroid. The label was visibly restricted to the cytoplasm of the cells which is a feature not evident in the earlier autoradiographic and fluorescence immunohistochemical studies.
Canine pharmacokinetics A peak concentration of CCI-103F was reached in the blood within 30 min of injection. Only low concentrations of the marker could be detected 24 h after its injection. The first order pharmacokinetic plot in Figure 2 shows the plasma concentrations of CCI-103F as a function of time after intravenous injection. Each point represents the mean and standard deviation of data derived from the nine dogs analysed to date. Regression analysis was used to calculate a mean plasma half-life of 7.9 h for CCI-103F. This compares with a shorter plasma half-life of 3.7 h for i.v. administered misonidazole (White et al., 1982) and 5.0 h for orally administered misonidazole (Creasey & Thrall, 1982) in dogs. A two-fold longer half-life for CCI-103F relative to misonidazole has also been observed for mice. This was attributed to the greater lipophilicity of CCI-103F ). There were no major metabolites of CCI-103 F detected at 320 nm in the HPLC chromatograms. In earlier studies involving the detection of radioactive metabolites, a seemingly prominent, polar metabolite appeared in the plasma of mice injected with tritiated CCI-103F . It is now known that the most abundant, tritiumcontaining polar metabolite under these circumstances is tritiated water which is formed in a minor pathway by the metabolic release of tritium from the sidechain of the labelled compounds . Blood count and routine serum chemistry analyses of blood samples drawn from the dogs injected with CCI-103F showed no significant abnormalities. Figure 1 Immunoperoxidase labelling of hypoxic cells in an EMT/6 spheroid incubated with CCI-103F in aerated medium. The labelled hypoxic cells are adjacent to the necrotic centre which is in the centre of the section. Spheroids which have not been exposed to CCI-103F show no labelling when the antibody to CCI-103F is applied to them (data not shown). The data points are the mean plasma concentrations for the nine dogs analysed to date. A plasma half-life for CCI-103F of 7.9 h can be calculated from these data.
Tumour fixation and staining
Various fixatives including cold 95% ethanol, 10% formalin, Bouin's fixative and Trump's fixative were compared. In spite of the generally favourable preservation reported for tissue antigens with cold ethanol fixation, it was found that cold 95% ethanol provided no advantage over the more convenient formalin-containing fixatives each of which provided better tissue preservation and section adhesion than did ethanol. Bouin's fixative produced a slightly higher nonspecific background staining than the other fixatives. In our hands, the peroxidase-antiperoxidase method of tissue staining gave a better hypoxia marker detectability against background than the staining produced by the avidin-biotin complex method.
Hypoxia marker detection
In general, the distribution of labelled cells in the tumours was consistent with the expected location of hypoxic cells in tissues for which oxygen concentration gradients are established by diffusion (Franko & Sutherland, 1979; Kallman, 1972; Thomlinson & Gray, 1955) . Labelled cells consistently appeared at distances of 10-12 cell diameters (100-1501 m) from blood vessels (Figures 3-6 ) independently of whether necrosis was present. This labelling pattern was easily discer- (Figure 3 ) whereas the heavily labelled haemangiopericytoma produced many fields of intense labelling ( Figure  5 ). The apparent difference in intensity of labelling between these two tumour types is not due to differing development conditions for the PAP staining but due to a difference in the number of cells labelled.
Occasionally, labelling was observed adjacent to tumour blood vessels (data not shown) which is similar to the results of earlier autoradiographic studies (Urtasun et al., 1986 ). The overall labelling pattern was independent of location within the tumour in the sense that samples taken from the margins of the tumours contained proportions of hypoxic cells similar to those taken from the centers of the same tumours. This is similar to the results for EMT6 mouse tumours (Chapman et al., 1981) . The immunohistochemical technique revealed that the labelling was discrete and restricted to the cytoplasm of the labelled cells (Figures 4, 6 Rectal adenocarcinoma 4 9 Figure 6 Higher magnification of the immunoperoxidase labelled tumour in Figure 5 . Bar = 50 ym. (Figure 7) . The cytoplasm of the myocytes was intensely labelled with an indication of enhanced labelling near the periphery of the nucleus. The labelling of the arteriole smooth muscle cells has not previously been reported. Earlier studies with rodents have indicated that normal tissues such as liver and skin are labelled by the hypoxia markers (Van Os-Corby et al., 1987; Franko et al., 1989; Cobb et al., 1990) but no investigation of these tissues was carried out on the canine patients.
Discussion
The distribution of the hypoxia marker in EMT6/Ed spheroids as detected by peroxidase immunohistochemistry is consistent with the expected location of hypoxic cells and is in agreement with previous results with fluorescence immunohistochemistry and autoradiography (Miller et al., 1989; Raleigh et al., 1987) . In general, the spheroid system, with its three-dimensional array of cells in which the oxygen gradient profile is well-characterised, is a useful test system for an hypoxic marker . Earlier autoradiographic studies in which the binding of tritium-labelled CCI-103F and the reference hypoxia marker, misonidazole, were compared showed that CCI-103F was indistinguishable from misonidazole in revealing oxygen profiles in EMT6 spheroids (Raleigh et al., 1987) . In those studies it appeared that CCI-103F might bind to aerobic cells to a greater extent than misonidazole. However, this conclusion was based on autoradiographic grain counts over aerobic cells where the number of grains is the lowest and the counting the least precise. There is no indication from the peroxidase results (Figure 1) or from quantitative immunofluorescence studies (Miller et al., 1989 ) that CCI-103F binds to a measurable extent to the outer aerobic cells in the spheriod. It is important at this stage of hypoxic marker development that a marker such as CCI-103F behaves in a manner analogous to that of misonidazole because of the extensive investigations both in vitro and in vivo which have been used to establish misonidazole as a marker of hypoxic cells (Franko et al., 1987; Chapman et al., 1981) . To a large extent, the inferences drawn from the binding patterns of CCI-103F in the sections of the spontaneous canine tumours reported here rest on the experimentally supported premise that misonidazole is a useful marker of in vivo tissue hypoxia and that CCI-103F mimics misonidazole in this regard.
Labelled cells in the excised canine tumours were generally observed to occur 10-12 cell diameters away from visible blood vessels in the tumour sections (Figures 3-7 ). This coincides with the expected diffusion distance of oxygen under normal physiological conditions (Franko & Koch, 1984; Franko & Sutherland, 1979; Kallman, 1972 ; Thomlinson & Gray, 1955) and indicates an unremarkable rate of oxygen consumption in the canine tumours relative to both rodent and human tumours studied to date. In addition, it is perhaps interesting that labelled tumour cells appeared in the absence of obvious necrosis. Necrosis has been an important landmark in the identification of hypoxic regions in tumours (Franko & Sutherland, 1979; Thomlinson & Gray, 1955) but the marker approach clearly indicates that hypoxic cells can exist in tumours in the absence of frank necrosis. It remains uncertain whether necrosis-associated hypoxic cells are viable and clonogenic and hence able to contribute to tumour radioresistance. The same question remains for the labelled cells in Figures 3-6 but there is no indication of severe nutrient deprivation such as the presence picnotic or degenerate cells which are frequently observed in the regions of frank necrosis.
The estimate of hypoxic fraction in the tumours by the immunohistochemical approach appears to be feasible (Table   I ). The procedure reproduces many of the observations of earlier autoradiographic studies including the observation that tumour size alone is not a useful predictor of the extent of hypoxia (Urtasun et al., 1986) . Compared to the autoradiographic approach, the immunohistochemical method is less time consuming and eliminates the need for radioactively labelled markers. It remains to be seen, however, whether the estimates of hypoxic fraction obtained here by morphometric analysis of randomly selected sections taken from throughout the tumours can be reproduced from data gathered by the more limited biopsy sampling expected in a clinical setting.
It is important to point out that the present results provide no information on the actual concentration of oxygen in the tumour tissues. However, the oxygen dependence of binding of misonidazole to hypoxic tissues has been shown to be similar to the oxygen dependence of radiation-induced cell killing (Franko et al., 1987) and it would appear from the spheroid results that CCI-103F shows a similar dependence.
Whether this binding will be predictive of tumour radiation response remains to be investigated.
In addition to the preceding considerations, the hypoxic fractions reported here must be considered as minimum values. Studies with transplantable rodent tumours (Hirst et al., 1982) have shown that tumour cells migrate from oxygenated to hypoxic regions at a rate of 1.1-2.2 jm h-as cells close to capillaries proliferate and hypoxic cells distant to capillaries are displaced into adjacent necrotic regions. While the mean potential doubling time for spontaneous canine tumours (5.4 ± 2.9 days; range 2.3-16 days) (Owen & Steel, 1969 ) is much greater than that for rodent tumours (1-2 days) and the cell migration rate in the spontaneous tumours might, therefore, be expected to be much lower, the possibility that previously well-oxygenated cells had migrated into the hypoxic regions by the end of the 24 h labelling period cannot be completely ruled out. The effect would be an apparent decrease in the hypoxic fraction because labelled hypoxic cells lost to necrosis would not have been counted in the morphometric analysis. The widespread occurrence of labelled cells in the spontaneous tumours in the absence of necrosis might have been interpreted to mean that cell migration processes were not occurring. However, the overall cell loss factors for rodent and spontaneous canine tumours are similar (Hirst et al., 1982; Owen & Steel, 1969) so that mechanisms of cell loss other than cell migration into necrotic regions may exist.
Autoradiographic studies of human tumours with radioactively labelled misonidazole revealed that tumour cells adjacent to blood vessels can be labelled even though these cells would be expected to be well-oxygenated. Similar labelling was occasionally observed in the canine tumours (data not shown). In the human tumours, this labelling was attributed to perfusion limited oxygen supply with intratumoral pressure implicated as a possible cause of blood vessel collapse during the labelling period (Urtasun et al., 1986) . Such labelling of the canine tumours indicates the generality of the phenomenon and, at the same time, shows that the immunohistochemical technique produces results consistent with the autoradiographic technique.
In both liver cells and parasites such as schistosomes, approximately 75% of the bioreductive binding of nitroheterocyclic compounds is to proteins (Smith, 1984; Tracy et al., 1983) . Thiol groups on proteins are likely to be major binding sites for the bioreductively activated nitroheterocyclic compounds (Chacon et al., 1988; Raleigh & Koch, 1990; Varghese, 1983) . In the case of the canine tumours, the in vivo binding of CCI-103F to tumour cells and to smooth muscle cells occurs primarily in the cytoplasm (Figures 4, 6 , and 7). This is consistent with protein being the predominant macromolecular binding moiety in these cases as well. Cytoplasmic ribonucleic acids can bind 2-nitroimidazoles with the same efficiency as proteins (Smith, 1984) . However, even though the polyclonal antibodies to CCI-103F detect only sidechain determinants (Raleigh et al., 1987) and could not, therefore, distinguish between RNA and protein binding, the protein abundance in cells is 14 times greater than that of RNA (Giese, 1968) (Guyton, 1979) . A similar estimate of 10 mmHg for some normal tissue cell P02 was made on the basis of the radiation response of a variety of normal tissues (Hendry, 1979 (Guyton, 1979) and endothelium-derived nitric oxide (Vanhoutte, 1988 In conclusion, the immunohistochemical approach described here shows promise as a technique for measuring tumour hypoxia. The approach may complement noninvasive techniques such as PET, MRI and gamma-ray scintigraphy and be particularly useful at low levels of hypoxic fraction where the non-invasive techniques are relatively insensitive. The comparison of immunohistochemical data on tumour hypoxia with other histological data such as cell type, degree of differentiation and proliferative status measured, for example, by 5-bromodeoxyuridine labelled S phase cells in the same tissue sections could also be instructive with respect to the development of predictive assays of radiation response. The binding of CCI-103F to the tumour cells is extensive and it may be possible that the cell surface binding is sufficient to permit sorting of labelled and unlabelled tumour cells by flow cytometry. Marker-directed immunotherapy of hypoxic cells is also conceivable but would be useful only if the binding to normal tissue could be selectively inhibited.
